Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prodyl C is a combination pharmaceutical product formulated as an oral syrup, containing the opioid antitussive codeine and the first-generation antihistamine triprolidine. Developed and marketed by Ravian Pharmaceuticals, it is indicated for the symptomatic relief of cough and upper respiratory symptoms associated with the common cold or allergic rhinitis. Codeine functions as a central cough suppressant by acting as an agonist at mu-opioid receptors in the medullary cough center, thereby increasing the cough threshold. Triprolidine provides relief from sneezing, rhinorrhea, and itchy eyes by competitively antagonizing histamine H1 receptors. As a commercial generic formulation, Prodyl C is used for the management of non-productive cough and associated allergic symptoms in pediatric and adult populations where approved.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + triprolidine.